Catalyst Pharmaceuticals (CPRX) Receivables - Net (2019 - 2026)

Catalyst Pharmaceuticals has reported Receivables - Net for 8 years, with the latest figure at $130.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 83.59% year-over-year to $130.8 million; the trailing twelve-month figure through Mar 2026 stood at $130.8 million (up 83.59% YoY), and the FY2025 full-year result was $126.5 million, up 93.17% from the prior year.
• Receivables - Net for Q1 2026 stood at $130.8 million, up from $126.5 million in the prior quarter.
• The five-year high for Receivables - Net was $130.8 million in Q1 2026, with the low at $9.3 million in Q3 2022.
• Historically, Receivables - Net has averaged $56.5 million across 5 years, with a median of $57.2 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 414.61% — and 2025, when it increased 15.2%.
• Catalyst Pharmaceuticals' Receivables - Net stood at $10.4 million in 2022, then surged by 412.64% to $53.5 million in 2023, then gained by 22.35% to $65.5 million in 2024, then soared by 93.17% to $126.5 million in 2025, then advanced by 3.44% to $130.8 million in 2026.
• The last three Receivables - Net figures came in at $130.8 million (Q1 2026), $126.5 million (Q4 2025), and $106.4 million (Q3 2025), per Business Quant data.